Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
Active, not recruiting · NCT04691661 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2026-09-03 | NCT04691661 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Il-Yang Pharm. Co., Ltd. | 6 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHRU de Lille - Hôpital Roger Salengro | Lille | France | 1 |
| CHU de Lyon HCL | Lyon | France | 1 |
| CHU de Rouen | Rouen | France | 37 |
| CHU La Miletrie | Poitiers | France | 3 |
| CHU Limoges | Limoges | France | 42 |
| Hôpital Nantes-Hotel Dieu | Nantes | France | 1 |
| Hôpital Pitié-Salpêtrière | Paris | France | 6 |